Table of contents
From the editors
p337 | doi:10.1038/nrc1907
Research Highlights
Multiple myeloma: Establishing order from chaos
p339 | doi:10.1038/nrc1899
RNA interference: New targets on the cards
p340 | doi:10.1038/nrc1900
Genomic instability: Beyond Boveri
p340 | doi:10.1038/nrc1903
Expression profiling: Developing patterns
p341 | doi:10.1038/nrc1895
Lung cancer: Transducing a mutant signal
p342 | doi:10.1038/nrc1898
Stem cells: Distinguishing features
p342 | doi:10.1038/nrc1901
In the news
Early optimism
p342 | doi:10.1038/nrc1904
In brief
Epigenetics | Tumour suppressors | Therapy | Telomeres
p343 | doi:10.1038/nrc1905
MicroRNA: Tiny new oncogenes
p344 | doi:10.1038/nrc1902
Trial Watch
Reduced skin rash with EGFR inhibitor | Activity in imatinib-resistant leukaemia
p344 | doi:10.1038/nrc1906
Expression profiling: Small but influential
p345 | doi:10.1038/nrc1896
Oncogenes: How much?
p345 | doi:10.1038/nrc1897
Reviews
Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia
Clemens Grabher, Harald von Boehmer & A. Thomas Look
p347 | doi:10.1038/nrc1880
NOTCH1 is activated in >50% of human T cell acute lymphoblastic leukaemia (T-ALL) samples and is far more important in this disease than previously suspected. How is Notch 1 activated and how does this further our understanding of the aetiology of T-ALL?
Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis
Yongfeng Shang
p360 | doi:10.1038/nrc1879
Both oestrogen and selective oestrogen receptor modulators can promote endometrial carcinogenesis. However, gene-expression studies have shown that they function through distinct, albeit overlapping, mechanisms. This article reviews our current understanding of both pathways.
Ubiquitin ligases: cell-cycle control and cancer
Keiichi I. Nakayama & Keiko Nakayama
p369 | doi:10.1038/nrc1881
Several ubiquitin ligases are altered in cancer. These proteins are crucial for the ubiquitin-mediated degradation of cell-cycle proteins, ensuring regulated progression through the cycle. Understanding the mechanistic roles of these ligases is therefore of great importance.
Is there more to BARD1 than BRCA1?
Irmgard Irminger-Finger & Charles Edward Jefford
p382 | doi:10.1038/nrc1878
BRCA1 interacts with many proteins, but one particular protein, BARD1, seems to be an important regulator of BRCA1 function. This review examines whether BARD1 has BRCA1-independent functions that contribute to the pathogenesis of cancer.
Article series: Tumour Microenvironment
Fibroblasts in cancer
Raghu Kalluri & Michael Zeisberg
p392 | doi:10.1038/nrc1877
Fibroblasts are an important component of the tumour microenvironment. They become activated in tumours, as they do in healing wounds. Here, their roles in tumour initiation, progression and metastasis are reviewed.
Perspectives
Opinion
The developing role of receptors and adaptors
Charles Massie & Ian G. Mills
p403 | doi:10.1038/nrc1882
Recent data indicate that growth-factor receptors and associated adaptors can accumulate in the nucleus. Are there novel functions for these proteins that might change our understanding of their role in cancer, and do these findings have implications for drug resistance?
Opinion
Measuring response in a post-RECIST world: from black and white to shades of grey
Laura C. Michaelis & Mark J. Ratain
p409 | doi:10.1038/nrc1883
The Response Evaluation Criteria in Solid Tumours (RECIST) guidelines are crucial to the assessment of new anticancer agents, but are they adequate for evaluating the activity of the newest generation of cancer drugs?